Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.
The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.
Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.
Experts in oncology discuss future directions in biomarker-driven therapy.
Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.
The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.
The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.
Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.
Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.
Kevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.
Narjust Florez (Duma), MD, discusses nihilism in small cell lung cancer.
Ralph Boccia, MD, and Jim Schwartz, RPh, discuss the overall impact the approval for trilaciclib will have on patients’ treatment outcomes, health care expenses, and quality of life.
Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.
Gunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.
Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.
YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.
Jill Alldredge, MD, discusses the toxicities associated with PARP inhibition and the management of those adverse effects in patients with ovarian cancer.
Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.
Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.
Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.
A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.
Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.
The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.
Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.
Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512